DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DOCS - US26622P1075 - Common Stock
44.28 USD
-0.3 (-0.67%)
44.2 USD
-0.08 (-0.18%)
Overall DOCS gets a fundamental rating of 7 out of 10. We evaluated DOCS against 35 industry peers in the Health Care Technology industry. Both the health and profitability get an excellent rating, making DOCS a very profitable company, without any liquidiy or solvency issues. DOCS is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes DOCS very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
DOCS had a positive operating cash flow in the past year.
DOCS had positive earnings in each of the past 5 years.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DOCS has a Return On Assets of 20.13%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
With an excellent Return On Equity value of 23.10%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Invested Capital of DOCS (18.16%) is better than 100.00% of its industry peers.
DOCS had an Average Return On Invested Capital over the past 3 years of 14.17%. This is significantly above the industry average of 6.61%.
The last Return On Invested Capital (18.16%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROIC | 18.16% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
Looking at the Profit Margin, with a value of 40.72%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
DOCS's Operating Margin of 39.72% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of DOCS has grown nicely.
DOCS has a Gross Margin of 90.20%. This is amongst the best in the industry. DOCS outperforms 97.14% of its industry peers.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DOCS is creating value.
The number of shares outstanding for DOCS has been increased compared to 1 year ago.
DOCS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
DOCS has an Altman-Z score of 33.18. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
DOCS has a Altman-Z score of 33.18. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 33.18 |
ROIC/WACC1.85
WACC9.82%
2.3 Liquidity
DOCS has a Current Ratio of 7.79. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.79, DOCS belongs to the best of the industry, outperforming 91.43% of the companies in the same industry.
DOCS has a Quick Ratio of 7.79. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
DOCS has a better Quick ratio (7.79) than 91.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.43% over the past year.
Measured over the past years, DOCS shows a very strong growth in Earnings Per Share. The EPS has been growing by 79.21% on average per year.
The Revenue has grown by 20.21% in the past year. This is a very strong growth!
DOCS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.42% yearly.
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
3.2 Future
DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.75% yearly.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.49% yearly.
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue Next Year14.06%
Revenue Next 2Y12.55%
Revenue Next 3Y12.02%
Revenue Next 5Y11.49%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 27.00, DOCS can be considered very expensive at the moment.
Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than 80.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. DOCS is around the same levels.
Based on the Price/Forward Earnings ratio of 25.28, the valuation of DOCS can be described as expensive.
DOCS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 68.57% of the companies in the same industry.
DOCS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27 | ||
| Fwd PE | 25.28 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DOCS is valued a bit cheaper than the industry average as 62.86% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, DOCS is valued a bit cheaper than the industry average as 71.43% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.71 | ||
| EV/EBITDA | 26.1 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.9
PEG (5Y)0.34
EPS Next 2Y11.46%
EPS Next 3Y11.79%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
44.28
-0.3 (-0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners91.34%
Inst Owner Change0.15%
Ins Owners1.96%
Ins Owner Change0.19%
Market Cap8.34B
Revenue(TTM)621.33M
Net Income(TTM)253.03M
Analysts77.04
Price Target69.67 (57.34%)
Short Float %5.99%
Short Ratio3.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.98%
Min EPS beat(2)16.41%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)25.31%
Min EPS beat(4)16.41%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)23.42%
EPS beat(12)12
Avg EPS beat(12)22.47%
EPS beat(16)16
Avg EPS beat(16)28.98%
Revenue beat(2)2
Avg Revenue beat(2)3.67%
Min Revenue beat(2)2.52%
Max Revenue beat(2)4.82%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.68%
Revenue beat(12)9
Avg Revenue beat(12)2.53%
Revenue beat(16)12
Avg Revenue beat(16)2.69%
PT rev (1m)-2.04%
PT rev (3m)-1.17%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.27%
EPS NY rev (1m)3.87%
EPS NY rev (3m)4.31%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)1.63%
Revenue NY rev (3m)1.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27 | ||
| Fwd PE | 25.28 | ||
| P/S | 13.42 | ||
| P/FCF | 26.71 | ||
| P/OCF | 26.07 | ||
| P/B | 7.61 | ||
| P/tB | 8.58 | ||
| EV/EBITDA | 26.1 |
EPS(TTM)1.64
EY3.7%
EPS(NY)1.75
Fwd EY3.96%
FCF(TTM)1.66
FCFY3.74%
OCF(TTM)1.7
OCFY3.84%
SpS3.3
BVpS5.82
TBVpS5.16
PEG (NY)1.9
PEG (5Y)0.34
Graham Number14.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROCE | 22.1% | ||
| ROIC | 18.16% | ||
| ROICexc | 85.05% | ||
| ROICexgc | 177.37% | ||
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% | ||
| FCFM | 50.23% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.81% | ||
| Cap/Sales | 1.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 123.66% | ||
| Profit Quality | 123.35% | ||
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 | ||
| Altman-Z | 33.18 |
F-Score9
WACC9.82%
ROIC/WACC1.85
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
Revenue Next Year14.06%
Revenue Next 2Y12.55%
Revenue Next 3Y12.02%
Revenue Next 5Y11.49%
EBIT growth 1Y22.24%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.72%
EBIT Next 3Y13.76%
EBIT Next 5Y14.23%
FCF growth 1Y94.7%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y93.3%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
What is the valuation status for DOCS stock?
ChartMill assigns a valuation rating of 4 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What are the PE and PB ratios of DOXIMITY INC-CLASS A (DOCS) stock?
The Price/Earnings (PE) ratio for DOXIMITY INC-CLASS A (DOCS) is 27 and the Price/Book (PB) ratio is 7.61.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 14.22% in the next year.